Market Intelligence, Clinical Progress, and High-Purity Reagents for Alpha-1D Adrenergic Receptor Targeted Therapeutics Development.
TarMart Solution Ecosystem & Related Targets
"Comprehensive reagent toolkit for ADRA1D drug discovery. Select your modality below:"
| Component / Network | Product Description | Product Link |
|---|---|---|
| Gene Delivery (Lentivirus) | ADRA1D Lentivirus Premade Particles: High titer (>10^8 TU/ml), qPCR Verified, full-length ORF for stable cell lines. Endotoxin Controlled. | View ADRA1D Products |
| Gene Delivery (Vector) | ADRA1D Promise-ORF Cloning Vector: Sequence Verified, Codon optimized. Ready for transfection. | View ADRA1D Products |
| Antigen (Membrane Lysate) | ADRA1D Overexpression Membrane Lysate: HEK293-derived full-length receptor. Sequence Verified. For binding and selectivity. | View ADRA1D Products |
| Antigen (Recombinant Protein) | ADRA1D Recombinant Protein (Partial/Loop): High purity (>95%), Endotoxin <1EU/ug. Sequence Verified. | View ADRA1D Products |
| Benchmark Ab | Anti-ADRA1D Antibody (Reference Clone/Monoclonal): Recombinant positive control for FACS, blocking, and binding assays. Sequence Verified. | View ADRA1D Products |
| Validator | ADRA1D siRNA Set (3 unique sequences): For knockdown verification, specificity control, and pathway screening. | View ADRA1D Products |
| Related Target A | ADRA1A (Alpha-1A): Predominant prostatic subtype; essential for α1-selectivity counter-screening and LUTS specificity. | View ADRA1A Products |
| Related Target B | ADRA1B (Alpha-1B): Vascular smooth muscle subtype; critical for cardiovascular safety profiling. | View ADRA1B Products |
| Critical Assay Challenge | The TarMart Advantage (Technical Spec) |
|---|---|
| Subtype Selectivity (vs ADRA1A/ADRA1B) | Human ADRA1A/ADRA1B/ADRA1D ortholog lentivirus panel and stable cell lines with matched titers (>10^8 TU/ml), sequence verified for rigorous counter-screening. |
| Native GPCR Conformation & Functional Validation | HEK293-expressed full-length receptor lentivirus for stable cell lines; preserves native glycosylation and membrane topology. Calcium flux validated for FLIPR/FDSS functional assays. |
| Cross-species Translation | Human/Mouse/Rat/Cyno ADRA1D lentivirus with sequence-verified ORFs for ortholog binding and in vivo relevance. |
| Assay Specificity Controls | Validated siRNA set (3 unique sequences) and reference antibodies included for knockdown confirmation and background-noise control. |
Live ADRA1D R&D Tracker
Market data changes daily. Access the latest global pipeline status directly:
Global Clinical Landscape & Future Outlook
The landscape for ADRA1D therapeutics is evolving from non-selective alpha-blockers (e.g., tamsulosin, doxazosin) toward highly subtype-selective antagonists and biased signaling modulators. First-generation agents effectively treat benign prostatic hyperplasia (BPH) and hypertension but cause dose-limiting hypotension (ADRA1B-mediated) and retrograde ejaculation (ADRA1A-mediated) due to lack of subtype selectivity. The next wave of R&D focuses on next-generation inhibitors that dissociate efficacy from cardiovascular side effects, with expanding indications into fibrosis, chronic pain, neurogenic bladder, and CNS disorders including PTSD. Key players include Astellas, Pfizer, Sanofi, and specialized biotechs exploring allosteric modulators and biologics. The clinical pipeline remains dominated by small molecules, but targeted peptides and monoclonal antibodies are entering preclinical stages.
Competitive Modality & Indication Snapshot
| Modality | Representative Focus | Key Indications | Critical Assay Need (Why TarMart?) |
|---|---|---|---|
| Small Molecule (Selective Antagonist) | Astellas, Pfizer, Sanofi, Generics | BPH, Hypertension, LUTS | Subtype Selectivity Panel (Need ADRA1A/1B/1D lentivirus cell lines for IC50 ratio determination) |
| GPCR-Biased Ligand & Allosteric Modulator | Specialized Biotech, Academic Labs | Fibrosis, Heart Failure, PTSD, Neurogenic Bladder | β-arrestin vs G-protein Assay (Need stable receptor lines for BRET/PathHunter) and Ortholog Binding (Need cross-species lentivirus) |
| Emerging Biologic / Peptide / Monoclonal Antibody | Emerging Biotechs, Preclinical Pipelines | Bladder Hypertrophy, Vascular Remodeling, Oncology Microenvironment | Cell Surface Epitope Binding (Need native conformation from HEK293 lentivirus stable cells; high-purity extracellular loops for immunization) |